AppClone announced on the 24th that it has developed the antibody therapeutic platform "mRMab" by merging messenger ribonucleic acid (mRNA) technology with existing antibody discovery technology.
Upcoming dividends for UNQUOTED ENTITLEMENT (INTERMEDIATE) SECURITY (MRMAB) are announced to the ASX several weeks before the ex-dividend date. To be a paid a dividend, you must own shares in UNQUOTED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results